We are a late-stage biopharmaceutical company committed to developing and commercializing products to treat rare diseases where there is an unmet medical need.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
SGX301 for Cutaneous T-Cell Lymphoma (CTCL)
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):